Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind randomized placebo-controlled study

Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease

“…Therefore any therapeutic intervention, such as strict control of blood pressure and inhibition of the RAS, that reduces the level of proteinuria is emphasised to prevent the progression of the decline in renal function 22 24 25. ARB treatment may decrease proteinuria by 30–50% in normotensive and hypertensive patients with IgA nephropathy 7 8 27 28. In our study, losartan treatment led to an average reduction in proteinuria of 30% after 3 months of treatment and 43% after 24 months.…”

Probucol combined with valsartan in immunoglobulin A nephropathy: A multi‐centre, open labelled, randomized controlled study

“…The rate of 24‐h urinary protein decrease after valsartan treatment in the present study is consistent with previous studies. For example, the HKVIN study of patients on ARBs showed that the 24‐h urinary protein was reduced from 1.80 ± 1.24 g at baseline to 1.26 ± 1.21 g at week 52, and to 1.23 ± 1.25 g at week 104 ( P < 0.001) . Previous study in the rat indicated that the antioxidant probucol, when added to an Ang II receptor blockade, fully arrests proteinuria and disease progression in GN …”

Chronic kidney disease epidemic: How do we deal with it?

“…Guideline published by the Kidney Disease: Improving Global Outcomes work group provides a comprehensive overview of management of glomerulonephritis . Supportive therapy including blood pressure control and blockade of renin angiotensin system remains the cornerstone in the treatment of IgAN . Although earlier evidence supported the use of steroid in patients with persistent proteinuria, the recently published Supportive versus immunosuppressive Therapy Of Progressive IgA Nephropathy trial questioned the benefit of immunosuppressant in addition to optimal supportive treatment .…”